Thanks for sharing… I was looking at the industry presentations (presentation slides are available in the link), and really caught my eye the numbers presented by ‘Medicines for Europe’
The extension of impact on NDSRIs is as prominent as we anticipated in our recent publication “The Landscape of Small and Drug Substance Related Nitrosamines in Pharmaceuticals”
